| 前收盘价格 | 0.435 |
| 收盘价格 | 0.461 |
| 成交量 | 638,411 |
| 平均成交量 (3个月) | 6,482,756 |
| 市值 | 114,175,024 |
| 预期市盈率 (P/E Forward) | 35.84 |
| 价格/销量 (P/S) | 51.64 |
| 股市价格/股市净资产 (P/B) | 5.01 |
| 52周波幅 | |
| 利润日期 | 12 Nov 2026 |
| 营业利益率 (TTM) | -4,484.33% |
| 稀释每股收益 (EPS TTM) | -0.690 |
| 总债务/股东权益 (D/E MRQ) | 228.93% |
| 流动比率 (MRQ) | 3.68 |
| 营业现金流 (OCF TTM) | -99.38 M |
| 杠杆自由现金流 (LFCF TTM) | -67.40 M |
| 资产报酬率 (ROA TTM) | -42.82% |
| 股东权益报酬率 (ROE TTM) | -249.75% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Humacyte, Inc. | 混合的 | 看涨 |
AIStockmoo 评分
0.5
| 分析师共识 | NA |
| 内部交易活动 | NA |
| 价格波动 | 0.5 |
| 技术平均移动指标 | 3.5 |
| 技术振荡指标 | -2.5 |
| 相对估值 | NA |
| 财务健康 | NA |
| AI Insight | NA |
| 平均 | 0.50 |
|
Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Growth |
| 内部持股比例 | 20.16% |
| 机构持股比例 | 40.20% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Antipodes Partners Ltd | 30 Jun 2026 | 10,103,647 |
| Great Point Partners I Lp | 30 Jun 2026 | 3,750,000 |
该时间范围内无数据。
该时间范围内无数据。
AI 技术分析
打开“技术”标签以生成最新分析。
投资组合